Please try another search
Nuvalent, Inc. is a clinical-stage biopharmaceutical company, which is focused on creating precisely targeted therapies for patients with cancer. Its lead product candidate, NVL-520 is a novel ROS1-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases. Its second lead product candidate, NVL-655, is a brain-penetrant ALK-selective inhibitor designed to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that may limit the use of first, second, and third generation ALK inhibitors. The Company’s product candidate also includes NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20, treating brain metastases, and avoiding treatment-limiting adverse events, including due to off-target inhibition of wild-type EGFR.
Name | Age | Since | Title |
---|---|---|---|
Matthew D. Shair | 54 | 2017 | Founder, Head of Scientific Advisory Board & Director |
James R. Porter | 47 | 2020 | CEO, President & Director |
Anna Protopapas | 58 | 2022 | Independent Chairman |
Sapna Srivastava | 52 | 2021 | Independent Non-Executive Director |
Emily Drabant Conley | 41 | 2022 | Independent Director |
Joseph Pearlberg | 58 | 2021 | Independent Non-Executive Director |
Alexander Drilon | - | 2021 | Member of Scientific Advisory Board |
Cameron A. Wheeler | 44 | 2017 | Independent Non-Executive Director |
Andrew A. F. Hack | 49 | 2021 | Independent Non-Executive Director |
Aaron Hata | - | - | Member of Scientific Advisory Board |
Nancy Kohl | - | - | Member of Scientific Advisory Board |
D. Ross Camidge | - | - | Member of Scientific Advisory Board |
D. Gary Gilliland | 68 | 2021 | Independent Non-Executive Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
Michael L. Meyers | 73 | 2022 | Member of Scientific Advisory Board & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review